A few other targets were also predicted to inhibit complement activation driven by CD59 and FH deficiency, however at a sustained target engagement requirement of 99% inhibition which posed uncertainty around feasibility of dosing high drug amounts to maintain high target inhibitions. This evidence concerns the gene CD59 and hyperinsulinemic hypoglycemia, familial, 4.